Summary:
1222.51: A randomised, double blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, co-administration of olodaterol 5 μg (delivered by the Respimat® Inhaler) and tiotropium 18 μg (delivered by the HandiHaler®) compared to once daily, orally inhaled, co-administration of placebo (delivered by the Respimat® Inhaler) and tiotropium 18 μg (delivered by the HandiHaler®) in patients with Chronic Obstructive Pulmonary Disease (COPD)
Qualified Participants Must:
• Be a current or former smoker
•
Have trouble breathing or a persistent cough
•
At least 40 years of age and healthy
•
Have no significant heart conditions
Qualified Participants May Receive:
Medication and study-related medical care at no cost while participating in the study and reimbursement for certain study related travel.